It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
There is currently an epidemic of opioid use, overdose, and dependence in the United States. Although opioid dependence (OD) is more prevalent in men, opioid relapse and fatal opioid overdoses have recently increased at a higher rate among women. Epigenetic mechanisms have been implicated in the etiology of OD, though most studies to date have used candidate gene approaches. We conducted the first epigenome-wide association study (EWAS) of OD in a sample of 220 European-American (EA) women (140 OD cases, 80 opioid-exposed controls). DNA was derived from whole blood samples and EWAS was implemented using the Illumina Infinium HumanMethylationEPIC array. To identify differentially methylated CpG sites, we performed an association analysis adjusting for age, estimates of cell proportions, smoking status, and the first three principal components to correct for population stratification. After correction for multiple testing, association analysis identified three genome-wide significant differentially methylated CpG sites mapping to the PARG, RERE, and CFAP77 genes. These genes are involved in chromatin remodeling, DNA binding, cell survival, and cell projection. Previous genome-wide association studies have identified RERE risk variants in association with psychiatric disorders and educational attainment. DNA methylation age in the peripheral blood did not differ between OD subjects and opioid-exposed controls. Our findings implicate epigenetic mechanisms in OD and, if replicated, identify possible novel peripheral biomarkers of OD that could inform the prevention and treatment of the disorder.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Yale University School of Medicine, Division of Human Genetics, Department of Psychiatry, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); VA CT Healthcare Center, West Haven, USA (GRID:grid.47100.32)
2 University of Pennsylvania Perelman School of Medicine, Department of Psychiatry, Center for Studies of Addiction and Crescenz Veterans Affairs Medical Center, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972)
3 Boston University School of Medicine, Departments of Psychiatry and Medicine (Biomedical Genetics), Boston, USA (GRID:grid.475010.7) (ISNI:0000 0004 0367 5222)
4 Yale University School of Medicine, Division of Human Genetics, Department of Psychiatry, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710); VA CT Healthcare Center, West Haven, USA (GRID:grid.47100.32); Yale University School of Medicine, Departments of Genetics and Neuroscience, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)